Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
Silence Therapeutics Analyst Ratings
Bullish on Silence Therapeutics: Buy Rating Affirmed Amid Strong Phase 2 Results for Zerlasiran
Silence Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)
Analysts Offer Insights on Healthcare Companies: Healthcare Services (HCSG), Gritstone Oncology (GRTS) and Silence Therapeutics (SLN)
Silence Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Silence Therapeutics (SLN) and Dyne Therapeutics (DYN)
Buy Rating for Silence Therapeutics: Strong Prospects for RNAi Platform and Drug Candidates
Silence Therapeutics Analyst Ratings
Solid Financial Status and Promising Clinical Trial Results Drive Buy Rating for Silence Therapeutics
HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Lowers Price Target to $75
Silence Therapeutics Analyst Ratings
Promising Outcomes From Silence Therapeutics' SLN360 Drug Trials Bolster Buy Rating Recommendation
Positive Phase I APOLLO Study Results Bolster Buy Rating for Silence Therapeutics
Analysts' Opinions Are Mixed on These Healthcare Stocks: Silence Therapeutics (SLN) and Monopar Therapeutics Inc (MNPR)
Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target
No Data